Focus on Anticoagulation Care

Back to articles

Extending enoxaparin thromboprophylaxis beneficial for some patients

KEY POINT

Results from a trial involving almost 6,000 acutely ill medical patients showed that extending enoxaparin prophylaxis for an additional 28 days after an initial 10-day course of therapy reduced the incidence of venous thromboembolism (VTE) events; however, this beneficial effect was seen only in subgroups of patients with level 1 immobility, those older than 75 years, and women. Extended-duration enoxaparin was also associated with an increased risk of major bleeding events.